Literature DB >> 9087920

Infectious agents in acute respiratory disease in horses in Ontario.

S Carman1, S Rosendal, L Huber, C Gyles, S McKee, R A Willoughby, E Dubovi, J Thorsen, D Lein.   

Abstract

A study of acute respiratory disease in horses in Ontario was undertaken to determine the identity of current causative infectious agents. A nasopharyngeal swab was designed and utilized to maximize isolation of viruses, mycoplasma, and pathogenic bacteria. Serum samples were collected for parallel determination of antibody titers to equine influenza virus type A subtype 1 (H7N7) and subtype 2 (H3N8), equine rhinovirus types 1 and 2, equine herpesvirus type 1, Mycoplasma equirhinius, and Mycoplasma felis. Equine rhinovirus type 2 was recovered from 28/92 horses tested, and equine influenza virus type A, subtype 2, was recovered from 5. The mycoplasma and bacteria isolated were consistent with those commonly associated with nonspecific respiratory diseases in horses, except that Streptococcus pneumoniae capsular type 3 was isolated from 10 horses.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9087920     DOI: 10.1177/104063879700900104

Source DB:  PubMed          Journal:  J Vet Diagn Invest        ISSN: 1040-6387            Impact factor:   1.279


  15 in total

1.  Genetic relatedness of recent Canadian equine influenza virus isolates with vaccine strains used in the field.

Authors:  Carl A Gagnon; Seyyed Mehdy Elahi; Donald Tremblay; Jean-Pierre Lavoie; Neil A Bryant; Debra M Elton; Susy Carman; Johanne Elsener
Journal:  Can Vet J       Date:  2007-10       Impact factor: 1.008

2.  A longitudinal study describing horse demographics and movements during a competition season in Ontario, Canada.

Authors:  Kelsey L Spence; Terri L O'Sullivan; Zvonimir Poljak; Amy L Greer
Journal:  Can Vet J       Date:  2018-07       Impact factor: 1.008

3.  Surveillance of equine respiratory viruses in Ontario.

Authors:  Andrés Diaz-Mendez; Laurent Viel; Joanne Hewson; Paul Doig; Susy Carman; Thomas Chambers; Ashish Tiwari; Catherine Dewey
Journal:  Can J Vet Res       Date:  2010-10       Impact factor: 1.310

4.  Association between respiratory disease and bacterial and viral infections in British racehorses.

Authors:  J L N Wood; J R Newton; N Chanter; J A Mumford
Journal:  J Clin Microbiol       Date:  2005-01       Impact factor: 5.948

5.  Evidence that Equine rhinitis A virus VP1 is a target of neutralizing antibodies and participates directly in receptor binding.

Authors:  S Warner; C A Hartley; R A Stevenson; N Ficorilli; A Varrasso; M J Studdert; B S Crabb
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

6.  Sequence conservation and antigenic variation of the structural proteins of equine rhinitis A virus.

Authors:  A Varrasso; H E Drummer; J A Huang; R A Stevenson; N Ficorilli; M J Studdert; C A Hartley
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

7.  Low-dose ginseng (Panax quinquefolium) modulates the course and magnitude of the antibody response to vaccination against equid herpesvirus I in horses.

Authors:  Wendy Pearson; Semir Omar; Andrew F Clarke
Journal:  Can J Vet Res       Date:  2007-07       Impact factor: 1.310

8.  Etiologic and epidemiologic analysis of bacterial infectious upper respiratory disease in Thoroughbred horses at the Seoul Race Park.

Authors:  Seung-Ho Ryu; Hye Cheong Koo; Young-Woo Lee; Yong Ho Park; Chang-Woo Lee
Journal:  J Vet Sci       Date:  2011-06       Impact factor: 1.672

9.  A longitudinal study of poor performance and subclinical respiratory viral activity in Standardbred trotters.

Authors:  Helena Back; Johanna Penell; John Pringle; Mats Isaksson; Nils Ronéus; Louise Treiberg Berndtsson; Karl Ståhl
Journal:  Vet Rec Open       Date:  2015-06-17

10.  Development of one-step TaqMan® real-time reverse transcription-PCR and conventional reverse transcription-PCR assays for the detection of equine rhinitis A and B viruses.

Authors:  Zhengchun Lu; Peter J Timoney; Jena White; Udeni Br Balasuriya
Journal:  BMC Vet Res       Date:  2012-07-25       Impact factor: 2.741

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.